Clene Inc. Common Stock (CLNN) is a publicly traded Healthcare sector company. As of May 21, 2026, CLNN trades at $6.72 with a market cap of $86.76M and a P/E ratio of -1.19. CLNN moved +7.60% today. Year to date, CLNN is +19.79%; over the trailing twelve months it is +165.38%. Its 52-week range spans $2.28 to $13.50. Analyst consensus is strong buy with an average price target of $32.20. Rallies surfaces CLNN's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Clene Eyes Q3 2026 CNM-Au8 NDA After Positive FDA Meeting, Raises $35M: Clene targets filing its NDA for CNM-Au8 under the accelerated approval pathway in Q3 2026 after a positive FDA Type C meeting. The company raised $35 million in recent offerings and extended its $10 million convertible debt maturity to August 2027, securing cash runway into late 2026.
| Metric | Value |
|---|---|
| Price | $6.72 |
| Market Cap | $86.76M |
| P/E Ratio | -1.19 |
| EPS | $-5.67 |
| Dividend Yield | 0.00% |
| 52-Week High | $13.50 |
| 52-Week Low | $2.28 |
| Volume | 201 |
| Avg Volume | 0 |
| Revenue (TTM) | $342.00K |
| Net Income | $-39.40M |
| Gross Margin | 79.53% |
5 analysts cover CLNN: 0 strong buy, 5 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $32.20.